CardiNor, Bioventix, Kaivogen, and Akershus University Hospital received €631k in Eurostars funding for Secretoneurin.

waving blue and yellow flag

CardiNor AS and its partners Bioventix Ltd, Kaivogen Oy and Akershus University Hospital have been granted Eurostars funding for the project: Secretoneurin, a breakthrough blood biomarker for heart disease and sudden cardiac arrest risk.

The total funding by the EU is €631,000.

The Eurostars project will support the following important milestones for the company:

  • Development and optimization of a simple test for measuring SN in the blood

  • Clinical validation using a very comprehensive patient material, which will also support and facilitate future CE marking

  • Optimization of assay production that will enable rapid commercialization

© 2026

Visiting address

c/o Horisont, Lørenveien 73A, 0585 Oslo

Part of

© 2026

Visiting address

c/o Horisont, Lørenveien 73A, 0585 Oslo

Part of

Visiting address

c/o Horisont, Lørenveien 73A, 0585 Oslo

Part of

Visiting address

c/o Horisont, Lørenveien 73A, 0585 Oslo

Part of